Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)
Editas Medicine (EDIT) posted quarterly Restructuring Costs of $26.1 million for Q2 2025, down 36.16% quarter-over-quarter from $40.9 million in Q1 2025.
Editas Medicine (EDIT) Restructuring Costs (2024 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Restructuring Costs for 2 consecutive years, with $26.1 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Restructuring Costs changed N/A year-over-year to $26.1 million; the TTM figure through Sep 2025 stood at $79.2 million (changed N/A YoY), while the FY2024 annual figure was $12.2 million, changed N/A from the prior year.
- Restructuring Costs declined to $26.1 million in Q2 2025 per EDIT's latest filing, from $40.9 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $40.9 million in Q1 2025 and bottomed at $12.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26.08 Mn |
| Mar 31, 2025 | 40.85 Mn |
| Dec 31, 2024 | 12.23 Mn |